| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-6018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-85 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2010-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f0f7758d1bb003155b5053bb9ce0426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cae3b6359b8d9d25ed14192f1030316 |
| publicationDate |
2012-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20120036688-A |
| titleOfInvention |
Improved gene delivery with tumor specific expression with recombinant gene expression control sequences |
| abstract |
The present invention relates to gene expression regulatory sequences consisting of a combination of HRE, E2F and TERT, and gene carriers, particularly recombinant adenoviruses, which have greatly improved selective tumor cell killing ability using the same. The present invention also relates to a pharmaceutical anti-tumor composition comprising the recombinant adenovirus. Recombinant adenovirus of the present invention exhibits an improved effect of selective tumor cell killing ability or high ability by controlling tumor-specific replication by a gene expression control sequence unique to the present invention. Indicates. In addition, specific expression of recombinant adenoviruses in cancer cells may increase stability in the body, leading to further improved anti-tumor effects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170106851-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019117632-A1 |
| priorityDate |
2010-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |